Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

Several authors disclosed ties to pharmaceutical companies, including AstraZeneca, which manufactures anifrolumab and funded the study. Touma Z, Bruce IN, Furie R, et al. Reduced organ damage ...

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...

AstraZeneca has, however, held on to anifrolumab, a late-stage phase 3 candidate being developed for the severe autoimmune disease lupus. "Autoimmune diseases represent one of the largest unmet ...

Potential therapeutic targets to address monocyte and macrophage involvement in IIMs include anti-CCR2, anti-GM-CSF, anti-CSF-1R, Nrf2 activators, PPAR-γ agonists, mesenchymal stem cell-derived ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim analysis. The trial hit on progression-free survival (PFS), its ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. The injectable drug will serve as an official partner of the Professional ...

AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday ...

Kiniksa Pharmaceuticals is stopping development of a midphase autoimmune asset and returning a drug candidate to AstraZeneca as it doubles down on its cardiovascular disease pipeline. The asset ...